1. HIV infection with plasma and CSF HIV RNA concentrations (using Roche Amplicor assay) > 1,000 copies/ mL (available after baseline LP). 
2. Off antiretroviral therapy (ART) for > 6 weeks before the study and no plans to begin treatment for the study duration. (The decision of whether or not a subject takes antiretroviral therapy will be made by the subject in consultation with his/her primary care provider prior to screening for this study.) 
3. Predicted adherence to the medication. 
4. Capable of providing informed consent. 
5. > 18 years old 
6. CD4 cell counts >150 cells/μL (though likely most, if not all, will be >250 cells/μL). 
7. When available, subjects will be screened for stability of blood CD4 and HIV RNA levels. 

NCT01064752_inc_T1
Condition
HIV infection
NCT01064752_inc_T2
Measurement
plasma concentration
NCT01064752_inc_T3
Measurement
CSF HIV RNA concentration
NCT01064752_inc_T4
Procedure
Roche Amplicor assay
NCT01064752_inc_T5
Value
> 1,000 copies/ mL
NCT01064752_inc_T6
Procedure
antiretroviral therapy (ART)
NCT01064752_inc_T7
Condition
Off antiretroviral therapy (ART)
NCT01064752_inc_T8
Temporal
> 6 weeks before the study
NCT01064752_inc_T9
Reference_point
the study
NCT01064752_inc_T10
Mood
plans to begin
NCT01064752_inc_T11
Procedure
treatment
NCT01064752_inc_T12
Temporal
for the study duration
NCT01064752_inc_T13
Reference_point
study
NCT01064752_inc_T14
Negation
no
NCT01064752_inc_T18
Value
18 years
NCT01064752_inc_T19
Person
old
NCT01064752_inc_T20
Measurement
CD4 cell counts
NCT01064752_inc_T21
Value
>150 cells/μL
NCT01064752_inc_T22
Value
>250 cells/μL